OZEM
Roundhill GLP-1 & Weight Loss ETF
The Roundhill GLP-1 & Weight Loss ETF seeks to provide investment exposure to companies involved in the development and commercialization of GLP-1 therapies and other weight loss solutions.
Global
EQUITY
Active
MANAGEMENT STYLE
36.0 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Fund sponsor | Roundhill |
| Category | Global |
| Asset class | Equity |
| Website | link... |
| Inception date | May 20, 2024 |
| Assets (mns) | $36 |
| Expense ratio | 59 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | |
| Taxation | 1099 |
| Stock selection | |
| Weighting | |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 17.1 % |
| NOVO-NORDISK A/S-SPONS ADR | 13.2 % |
| TERNS PHARMACEUTICALS, INC. | 6.0 % |
| VIKING THERAPEUTICS, INC. | 5.9 % |
| METSERA INC | 5.7 % |
| STRUCTURE THERAPEUTICS INC | 5.2 % |
| ROCHE HOLDING LTD | 4.7 % |
| CHUGAI PHARMACEUTICAL CO LTD | 4.7 % |
| ZEALAND PHARMA A/S | 4.5 % |
| AMGEN INC | 3.7 % |
Constituent Breakdown
| Number of holdings | 21 |
| Herfindahl-Hirschman Index | 750 |
| Wgt avg mkt cap (mns) | $192,711 |
| Large cap (>$10bn) | 64.5% |
| Mid cap ($2-10bn) | 19.7% |
| Small cap (<$2bn) | 2.7% |
| Developed mkts. | 86.8% |
| Emerging mkts. | 6.2% |
Country Exposure
 |
UNITED STATES | 51.3 % |
 |
DENMARK | 17.7 % |
 |
JAPAN | 5.9 % |
 |
SWITZERLAND | 4.7 % |
 |
BRITAIN | 3.5 % |
 |
CHINA | 3.3 % |
 |
SOUTH KOREA | 3.2 % |
 |
HONG KONG | 2.9 % |
Historical Performance
Standardized Performance (as of 10/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 17.9% | 5.0% | -- | -- | -- | -- | -- | 8.9% |
| Dividend Yield | 0.0% | 0.0% | -- | -- | -- | -- | -- | 0.0% |
| Total Returns | 17.9% | 5.0% | -- | -- | -- | -- | -- | 8.9% | Ann. Volatility | 27.2% | 27.0% | -- | -- | -- | -- | -- | 25.6% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.65 | 14% |
| MSCI EAFE | 0.02 | 0% |
| MSCI Emg Mkts | -0.15 | 1% |
Liquidity Measures
| Avg. volume (000) | 9 |
| ADV traded (mns) | $0 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.53% |
Technical Indicators
| Recent close | $29.49 |
| 30d moving avg. | $28.41 |
| Annualized volatility | 18.6% |
| Relative strength (RSI) | 62 |
| Short interest | 1.4% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. |
Expenses vs. |
ALTAR Score™ vs. |
|---|---|---|---|---|
| THNR | Amplify Weight Loss Drug & Treatment ETF | 63.4% | 0 bp | +7.5% |
| PPH | VanEck Pharmaceutical ETF | 30.2% | -23 bp | +8.3% |
| MEDX | Horizon Kinetics Medical ETF | 29.7% | +26 bp | +1.3% |
| XLV | The Health Care Select Sector SPDR Fund | 22.7% | -51 bp | +7.4% |
| IYH | iShares U.S. Healthcare ETF | 22.2% | -19 bp | +6.6% |
| IHE | iShares U.S. Pharmaceuticals ETF | 20.6% | -19 bp | +7.3% |
| IXJ | iShares Global Healthcare ETF | 20.5% | -17 bp | +7.0% |
| VHT | Vanguard Health Care ETF | 20.1% | -50 bp | +5.8% |
| HRTS | Tema Heart & Health ETF | 19.7% | +16 bp | +2.3% |
| RVER | Trenchless Fund ETF | 17.8% | +6 bp | +3.0% |
Risk and Returns: OZEM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/10/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
NEUTRAL
Average appreciation potential. A rating of NEUTRAL is assigned to ETFs with ALTAR Scores in the middle quintile (ranking between 40%-60%) of their category. This indicates that valuations adequately reflect the fundamentals of stocks in these funds.
ALTAR Score™
OZEM
3.7%
Cat. Avg
4.3%
ALTAR Score™ Calculation
Category Overview
There are 371 funds in the Global Equity category, with an average ALTAR Score™
of 4.3% and a standard deviation of
3.2%. OZEM's ALTAR Score™ is approximately
0.2 standard deviations
below
the category average. This places OZEM in the 42nd percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
OZEMSELL
U/W
HOLD
O/W
BUY